EUCTR2014-001408-23-IT进行中（未招募）1 期
AB-PACLITAXEL (ABRAXANE®) PLUS GEMCITABINE IN SUBJECTS WITH LOCALLY ADVANCED PANCREATIC CANCER (LAPC): AN INTERNATIONAL, OPEN-LABEL, MULTI-CENTER, PHASE 2 STUDY (LAPACT) - LAPACT
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 107
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Non- metastasis, unresectable, adenocarcinoma pancreatic cancer patients
- •No prior anticancer therapy for pancreatic cancer
- •= 18 years of age with a performance status of 0 or 1
- •Adequate complete blood counts, hepatic function, and renal function
- •Signed informed Consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 33
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 77
排除标准
- •Active bacterial, viral, or fungal infection
- •Infection with hepatitis B or C, or history of human immunodeficiency virus (HIV) infection, or receiving immunosuppressive or myelosuppressive
- •Subjects with sensory neuropathy, ascites, or plastic biliary stent.
- •Serious medical risk factors involving any of the major organ systems, or serious psychiatric disorders (including but not limited to connective tissue disorders, lung disease, and cardiac or seizure disorders)
- •Women who are pregnant or breast feeding
研究者
相似试验
进行中（未招募）
1 期
TRIAL OF ABRAXANE AND GEMCITABINE TO TREATMENT PANCREATIC CANCER PATIENTS WHO CAN NOT HAVE SURGERY BECAUSE OF CANCER LOCATIOocally advanced pancreatic cancerMedDRA version: 17.1Level: LLTClassification code 10033606Term: Pancreatic cancer non-resectableSystem Organ Class: 100000004864EUCTR2014-001408-23-ESCelgene Corporation110
进行中（未招募）
1 期
ab-Paclitaxel (Abraxane®) and Gemcitabine as first line therapy in patients with cholangiocarcinoma - The NACHO trialEUCTR2014-004981-52-DEniversity Hospital Essen10
未知
不适用
PHASE III STUDY OF GEMCITABIN WITH PACLITAXEL VERSUS PACLITAXEL IN PATIENTS WITH NON-RESECTIOUS, METASTASIC OR LOCALLY ADVANCED BREAST CANCER-C50 Malignant neoplasm of breastMalignant neoplasm of breastC50PER-059-01ELI LILLY INTERAMERICA INC.,
尚未招募
3 期
Assessment of prolongation of life with 2 different chemotherapy regimens - Gemcitabine – Cisplatin – Nab-Paclitaxel (GAP) and gemcitabine-platinum (GP) combination in advanced gallbladder cancers.CTRI/2024/01/061479Tata Memorial Centre
进行中（未招募）
1 期
GEMCITABINE-OXALIPLATINE PLUS RITUXIMAB (R-GEMOX) IN REFRACTORY/RELAPSED PATIENTS WITH CD20 POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA, NON ELIGIBLE FOR HIGH-DOSE CHEMOTHERAPY FOLLOWED BY AUTOTRANSPLANTATION - R-GEMOXRefractory/relapsed patients with CD 20 positive large B-cell lymphomaEUCTR2005-002344-26-BEGELA